|
US173A
(en)
|
|
1837-04-20 |
|
Improvement in the manufacture of hat-bodies |
|
US6683A
(en)
|
|
1849-08-28 |
|
And john w |
|
CH445129A
(fr)
|
1964-04-29 |
1967-10-15 |
Nestle Sa |
Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
|
|
US3459731A
(en)
|
1966-12-16 |
1969-08-05 |
Corn Products Co |
Cyclodextrin polyethers and their production
|
|
US3426011A
(en)
|
1967-02-13 |
1969-02-04 |
Corn Products Co |
Cyclodextrins with anionic properties
|
|
US3453257A
(en)
|
1967-02-13 |
1969-07-01 |
Corn Products Co |
Cyclodextrin with cationic properties
|
|
US3453259A
(en)
|
1967-03-22 |
1969-07-01 |
Corn Products Co |
Cyclodextrin polyol ethers and their oxidation products
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US5190931A
(en)
|
1983-10-20 |
1993-03-02 |
The Research Foundation Of State University Of New York |
Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
JP3022967B2
(ja)
|
1985-03-15 |
2000-03-21 |
アンチバイラルズ インコーポレイテッド |
立体規則性ポリヌクレオチド結合ポリマー
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US20020123476A1
(en)
|
1991-03-19 |
2002-09-05 |
Emanuele R. Martin |
Therapeutic delivery compositions and methods of use thereof
|
|
US5508337A
(en)
|
1992-02-11 |
1996-04-16 |
Bayer Aktiengesellschaft |
Powder coating compositions, a process for their preparation, and their use for the coating of heat resistant substrates
|
|
EP0633944B1
(en)
|
1992-03-31 |
2000-11-08 |
Abbott Laboratories |
Method of multiplex ligase chain reaction
|
|
US5869252A
(en)
|
1992-03-31 |
1999-02-09 |
Abbott Laboratories |
Method of multiplex ligase chain reaction
|
|
US6806084B1
(en)
|
1992-06-04 |
2004-10-19 |
The Regents Of The University Of California |
Methods for compositions for in vivo gene delivery
|
|
WO1994002595A1
(en)
|
1992-07-17 |
1994-02-03 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of animal diseases
|
|
US5985558A
(en)
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
|
DE69435005T2
(de)
|
1993-05-11 |
2008-04-17 |
The University Of North Carolina At Chapel Hill |
Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
|
|
US5801154A
(en)
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
|
US6391636B1
(en)
|
1994-05-31 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
IL115849A0
(en)
|
1994-11-03 |
1996-01-31 |
Merz & Co Gmbh & Co |
Tangential filtration preparation of liposomal drugs and liposome product thereof
|
|
GB9510718D0
(en)
|
1995-05-26 |
1995-07-19 |
Sod Conseils Rech Applic |
Antisense oligonucleotides
|
|
WO1997030067A1
(en)
|
1996-02-14 |
1997-08-21 |
Isis Pharmaceuticals, Inc. |
Sugar-modified gapped oligonucleotides
|
|
AU2585197A
(en)
|
1996-03-20 |
1997-10-10 |
Regents Of The University Of California, The |
Antisense approach to gene inhibition
|
|
US6153436A
(en)
|
1997-01-10 |
2000-11-28 |
The Board Of Trustees Of The University Of Arkansas |
Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions
|
|
WO1999042091A2
(en)
|
1998-02-19 |
1999-08-26 |
Massachusetts Institute Of Technology |
Use of polycations as endosomolytic agents
|
|
US6683173B2
(en)
|
1998-04-03 |
2004-01-27 |
Epoch Biosciences, Inc. |
Tm leveling methods
|
|
US20030114401A1
(en)
|
2001-12-06 |
2003-06-19 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Ship-1 expression
|
|
GB9819999D0
(en)
|
1998-09-14 |
1998-11-04 |
Univ London |
Treatment of cancer
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
WO2000028980A2
(en)
|
1998-11-13 |
2000-05-25 |
Eli Lilly And Company |
Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
|
|
EP1173561A2
(en)
|
1999-01-29 |
2002-01-23 |
Avi Biopharma, Inc. |
Non-invasive method for detecting target rna
|
|
US20020049173A1
(en)
|
1999-03-26 |
2002-04-25 |
Bennett C. Frank |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
|
NZ515964A
(en)
|
1999-06-21 |
2004-03-26 |
Murdoch Childrens Res Inst |
A method for the prophylaxis and/or treatment of medical disorders
|
|
US7070807B2
(en)
|
1999-12-29 |
2006-07-04 |
Mixson A James |
Branched histidine copolymers and methods for using same
|
|
CA2394758A1
(en)
|
1999-12-29 |
2001-07-05 |
A. James Mixson |
Histidine-containing copolymers enhance pharmaceutical agent delivery
|
|
WO2001049775A2
(en)
|
2000-01-04 |
2001-07-12 |
Avi Biopharma, Inc. |
Antisense antibacterial cell division composition and method
|
|
CA2400573A1
(en)
|
2000-03-28 |
2001-10-04 |
Isis Pharmaceuticals Inc. |
Alteration of cellular behavior by antisense modulation of mrna processing
|
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
|
WO2001083695A2
(en)
|
2000-04-28 |
2001-11-08 |
Xiao Xiao |
Dna sequences encoding dystrophin minigenes and methods of use thereof
|
|
AU2001257366B2
(en)
|
2000-05-01 |
2006-03-16 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
KR20020097241A
(ko)
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
|
JP4836366B2
(ja)
|
2000-08-25 |
2011-12-14 |
雅文 松尾 |
デュシェンヌ型筋ジストロフィー治療剤
|
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
|
CA2421043C
(en)
|
2000-08-30 |
2012-07-31 |
Avi Biopharma, Inc. |
Method for analysis of oligonucleotide analogs
|
|
US20070037165A1
(en)
|
2000-09-08 |
2007-02-15 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
AU2001289085A1
(en)
|
2000-09-20 |
2002-04-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of flip-c expression
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
US6689615B1
(en)
|
2000-10-04 |
2004-02-10 |
James Murto |
Methods and devices for processing blood samples
|
|
JP3781687B2
(ja)
|
2001-02-23 |
2006-05-31 |
松下電器産業株式会社 |
遺伝子診断装置及び遺伝子診断方法
|
|
US6656732B1
(en)
|
2001-05-18 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of src-c expression
|
|
DE60231975D1
(de)
|
2001-05-24 |
2009-05-28 |
Genzyme Corp |
Muskelspezifische expressionsvektoren
|
|
US20030224353A1
(en)
|
2001-10-16 |
2003-12-04 |
Stein David A. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
EP2213738B1
(en)
|
2002-11-14 |
2012-10-10 |
Dharmacon, Inc. |
siRNA molecules targeting Bcl-2
|
|
US7250289B2
(en)
|
2002-11-20 |
2007-07-31 |
Affymetrix, Inc. |
Methods of genetic analysis of mouse
|
|
US7314750B2
(en)
|
2002-11-20 |
2008-01-01 |
Affymetrix, Inc. |
Addressable oligonucleotide array of the rat genome
|
|
ES2509140T3
(es)
|
2002-11-25 |
2014-10-17 |
Masafumi Matsuo |
Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm
|
|
WO2004083432A1
(en)
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
CA2523672C
(en)
|
2003-04-29 |
2012-07-17 |
Avi Biopharma, Inc. |
Compositions for enhancing transport of molecules into cells
|
|
DE60319354T2
(de)
|
2003-07-11 |
2009-03-26 |
Lbr Medbiotech B.V. |
Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen
|
|
EP1654363B1
(en)
|
2003-08-05 |
2010-12-15 |
AVI BioPharma, Inc. |
Oligonucleotide analog and method for treating flavivirus infections
|
|
US20050048495A1
(en)
|
2003-08-29 |
2005-03-03 |
Baker Brenda F. |
Isoform-specific targeting of splice variants
|
|
AU2004273828A1
(en)
|
2003-09-12 |
2005-03-31 |
Avi Biopharma, Inc. |
Compound and method for treating androgen-independent prostate cancer
|
|
US20050171044A1
(en)
|
2003-12-24 |
2005-08-04 |
Stein David A. |
Oligonucleotide compound and method for treating nidovirus infections
|
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
EP3808845A1
(en)
|
2004-06-28 |
2021-04-21 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
FR2873294B1
(fr)
|
2004-07-26 |
2008-05-09 |
Greenpharma Sa Sa |
Association de medicaments
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
US20060148740A1
(en)
|
2005-01-05 |
2006-07-06 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
ES2852549T3
(es)
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
|
CA2605512A1
(en)
|
2005-04-22 |
2006-10-26 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
US8501703B2
(en)
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
US8524676B2
(en)
|
2005-09-08 |
2013-09-03 |
Sarepta Therapeutics, Inc. |
Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
|
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
|
CA2629323A1
(en)
|
2005-11-10 |
2007-05-24 |
The University Of North Carolina At Chapel Hill |
Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
|
|
US20090011004A1
(en)
|
2005-12-30 |
2009-01-08 |
Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine |
Improved carriers for delivery of nucleic acid agents to cells and tissues
|
|
US8785407B2
(en)
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
PL2735568T3
(pl)
|
2006-05-10 |
2018-02-28 |
Sarepta Therapeutics, Inc. |
Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
|
|
US20070265215A1
(en)
|
2006-05-11 |
2007-11-15 |
Iversen Patrick L |
Antisense restenosis composition and method
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
BE1017460A6
(nl)
|
2007-02-09 |
2008-10-07 |
Leo Vermeulen Consulting Lvc |
Lenticulair folie.
|
|
US8251804B2
(en)
|
2007-04-23 |
2012-08-28 |
Wms Gaming Inc. |
Gaming system having progressive jackpots flexibly linked with common progressive pool
|
|
EP2170363B1
(en)
|
2007-06-29 |
2018-08-08 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
PT2203173E
(pt)
|
2007-10-26 |
2016-03-15 |
Academisch Ziekenhuis Leiden |
Resumo
|
|
US8299206B2
(en)
|
2007-11-15 |
2012-10-30 |
Avi Biopharma, Inc. |
Method of synthesis of morpholino oligomers
|
|
US8076476B2
(en)
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
|
WO2009101399A1
(en)
|
2008-02-12 |
2009-08-20 |
Isis Innovation Limited |
Treatment of muscular dystrophy using peptide nucleic acid ( pna)
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
*
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CA3066050A1
(en)
|
2008-10-24 |
2010-04-29 |
Sarepta Therapeutics, Inc. |
Multiple exon skipping compositions for dmd
|
|
ES2532634T5
(es)
|
2008-10-27 |
2018-04-30 |
Biomarin Technologies B.V. |
Procedimientos y medios para el salto eficiente del exón 45 en el pre-ARNm de la distrofia muscular de Duchenne
|
|
AU2009335740B2
(en)
|
2008-12-17 |
2016-04-21 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
EP2417257B1
(en)
|
2009-04-10 |
2016-03-09 |
Association Institut de Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
ES2593836T3
(es)
|
2009-04-24 |
2016-12-13 |
Biomarin Technologies B.V. |
Oligonucleótido que comprende una inosina para tratar la DMD
|
|
WO2010136417A1
(en)
|
2009-05-25 |
2010-12-02 |
Università Degli Studi Di Roma "La Sapienza" |
miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY
|
|
EP2258863A1
(en)
|
2009-05-25 |
2010-12-08 |
Universita'Degli Studi di Roma "La Sapienza" |
miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
ITTO20090487A1
(it)
|
2009-06-26 |
2010-12-27 |
Univ Ferrara |
Oligonucleotidi antisenso atti ad indurre lo skipping esonico e loro impiego come medicamento per il trattamento della distrofia muscolare di duchenne (dmd)
|
|
WO2011024077A2
(en)
|
2009-08-31 |
2011-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Exon skipping therapy for functional amelioration of semi functional dystrophin in becker and duchenne muscular dystrophy
|
|
IT1397011B1
(it)
|
2009-10-14 |
2012-12-20 |
Univ Ferrara |
Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.
|
|
SI2499249T1
(sl)
|
2009-11-12 |
2019-02-28 |
The University Of Western Australia, |
Protismiselne molekule in postopki zdravljenja patologij
|
|
BR112012011381B8
(pt)
|
2009-11-13 |
2021-05-25 |
Avi Biopharma Inc |
oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo
|
|
US20120309684A1
(en)
*
|
2009-11-30 |
2012-12-06 |
Isis Innovation Limited |
Conjugates for delivery of biologically active compounds
|
|
US9050373B2
(en)
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
|
KR102095478B1
(ko)
|
2010-05-28 |
2020-04-01 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
CN103096928A
(zh)
|
2010-06-28 |
2013-05-08 |
萩原正敏 |
遗传性疾病的预防/改善剂
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
HUE030292T2
(en)
|
2010-09-30 |
2017-04-28 |
Nippon Shinyaku Co Ltd |
Morpholino-nucleic acid derivatives
|
|
CA2826836A1
(en)
|
2011-02-08 |
2012-08-16 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Antisense oligonucleotides
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
KR102339196B1
(ko)
|
2011-05-05 |
2021-12-15 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
펩타이드 올리고뉴클레오타이드 접합체
|
|
CN102856180B
(zh)
|
2011-06-30 |
2016-05-25 |
中国科学院微电子研究所 |
一种半导体器件的替代栅集成方法
|
|
WO2013033407A2
(en)
|
2011-08-30 |
2013-03-07 |
The Regents Of The University Of California |
Identification of small molecules that enhance therapeutic exon skipping
|
|
US20140080896A1
(en)
|
2011-08-30 |
2014-03-20 |
The Regents Of The University Of California |
Identification of small molecules that facilitate therapeutic exon skipping
|
|
ES2535654T3
(es)
|
2011-10-13 |
2015-05-13 |
Association Institut De Myologie |
ADN triciclo-fosforotioato
|
|
CN117721110A
(zh)
|
2011-12-28 |
2024-03-19 |
日本新药株式会社 |
反义核酸
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
CA2868174A1
(en)
*
|
2012-03-20 |
2013-09-26 |
Sarepta Therapeutics, Inc. |
Boronic acid conjugates of oligonucleotide analogues
|
|
JP6460983B2
(ja)
|
2012-07-03 |
2019-01-30 |
バイオマリン テクノロジーズ ベー．フェー． |
筋ジストロフィー患者の治療のためのオリゴヌクレオチド
|
|
EP3885439A1
(en)
|
2012-12-20 |
2021-09-29 |
Sarepta Therapeutics, Inc. |
Improved exon skipping compositions for treating muscular dystrophy
|
|
EP3760720A1
(en)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
IL280443B
(en)
|
2013-03-14 |
2022-07-01 |
Sarepta Therapeutics Inc |
Preparations that skip axon for the treatment of muscular dystrophy
|
|
MX373959B
(es)
*
|
2013-03-15 |
2020-07-13 |
Sarepta Therapeutics Inc |
Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd).
|
|
CA3201710A1
(en)
|
2013-04-20 |
2014-10-23 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
|
|
US9505058B2
(en)
|
2014-05-16 |
2016-11-29 |
Xerox Corporation |
Stabilized metallic nanoparticles for 3D printing
|
|
US20190054113A1
(en)
|
2015-09-30 |
2019-02-21 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|